NICE rejects Kadcyla as too expensive for HER2 positive Breast Cancer - Roche
The National Institute for Health and Care Excellence (NICE) in draft guidance has rejected Kadcyla (trastuzumab emtansine) or T-DM1, from Roche as at �90,000 per patient and providing patients an average of 5.8 extra months of life, it is six times more expensive than drugs normally approved for use on the NHS. The drug is an antibody-drug conjugate (ADC) that is a follow-up to Roche's successful Herceptin (trastuzumab), and being appraised by NICE as a second-line treatment option for people with advanced HER2-positive Breast Cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins